Chul Kim

3.6K posts

Chul Kim banner
Chul Kim

Chul Kim

@chulkimMD

Director of Thoracic Oncology at Georgetown University @Lombardicancer / Lung Cancer, Thymic Tumors, Phase I / #SoMeEditor @ClinicalLung / Secretary of ITMIG

Washington, DC Katılım Şubat 2017
886 Takip Edilen3.7K Takipçiler
Chul Kim retweetledi
Tejas Patil
Tejas Patil@TejasPatilMD·
@ASCO LUNG ABSTRACTS MEGA-THREAD ⭐️I've said it before; #ASCO26 is like a giant music festival - the @coachella of oncology 🎵You have the headliners [plenaries], acts on the main stages [halls B & D], & indie gems on the side [posters] 🎗️My PERSONAL list of the MOST interesting abstracts and WHY I think they are great! 🧵
Tejas Patil tweet media
English
1
13
53
3.8K
Chul Kim retweetledi
Ana I. Velázquez Mañana, MD, MSc, FASCO
🫁 As you build your schedule for #ASCO26, don’t miss (or 🔖 bookmark to watch later) several interesting #LungCancer abstracts being presented outside the lung cancer tracks. Some highlights include ⬇️ 1️⃣ ctDNA Clinical Science Symposium: FLAME: osimertinib ± chemotherapy in EGFRm NSCLC with persistent ctDNA+ after 3 weeks on 1L osimertinib 2️⃣ #GlobalOnc #CareDelivery Clinical Science Symposium: Low-dose pembrolizumab + chemotherapy in 1L advanced NSCLC 3️⃣ CNS Tumors Oral Abstracts: ESAONA: asandeutertinib vs. osimertinib in 1L EGFRm NSCLC with brain metastases #LCSM #ASCO26 @ASCO @OncBrothers @OncoAlert
Ana I. Velázquez Mañana, MD, MSc, FASCO tweet media
English
1
16
32
1.6K
Chul Kim retweetledi
Laura Alder, MD
Laura Alder, MD@LauraAlderMD·
Excited to see the full presentation #ASCO26 by @LaurenByersMD on ABBV-706, a SEZ6 ADC with promising activity in relapsed/refractory #SCLC! 📊 Key results: • ORR 82% in 2L pts (1.8 mg/kg) ‼️ • mOS 14.3 mo in 2L monotherapy • 15-mo OS rate: 50% • Combo w/ budigalimab (anti-PD-1): ORR 55%, mPFS 8.1 mo, no new safety signals ⭐️No treatment-related deaths. No pneumonitis with combo! (small n) An ADC target in SCLC worth watching !! 👀 @drshieldsmd @ASCO #lcsm @alissajcooper
Laura Alder, MD tweet media
English
2
16
38
2.2K
Chul Kim
Chul Kim@chulkimMD·
Join us tomorrow for a webinar on clinical trials and emerging therapies in thymic epithelial tumors, featuring an outstanding panel of experts discussing advances in targeted therapy, immunotherapy, ADCs, and radiotherapy! Register: bit.ly/4dELVTG @Itmig_society
Chul Kim tweet media
English
0
5
11
1.1K
Chul Kim retweetledi
Laura Alder, MD
Laura Alder, MD@LauraAlderMD·
🧵 CROWN 7-Year Update: Lorlatinib in 1L ALK+ NSCLC: the longest PFS ever reported in advanced NSCLC keeps getting longer!!! #ASCO26 🫁 Abstracts! Presenter: @TonyMok9 Key takeaways: 👇 @ALKPositiveinc 1) 1/ 📈 Median PFS STILL not reached at 7 years. • 7-yr PFS rate: 55% (lorlatinib) vs 3% (crizotinib), HR 0.19 • 44% of pts STILL on lorlatinib vs just 3% on crizotinib
Laura Alder, MD tweet media
English
6
42
119
16.3K
Chul Kim retweetledi
Laura Alder, MD
Laura Alder, MD@LauraAlderMD·
Excited to be selected as an #ASCO26 Featured Voice, along with esteemed colleagues and friends!! It's going to be an incredible meeting! From practice-changing lung cancer trials to landmark plenary sessions across oncology, there is SO much to cover. 🫁 Can't wait to share the science, the data, and what it means for our patients. Follow along! 🧵👇 @lungoncdoc @ASCO #lcsm graphics: @ADesaiMD, @Latinamd
Laura Alder, MD tweet mediaLaura Alder, MD tweet mediaLaura Alder, MD tweet media
ASCO@ASCO

We’re pleased to announce our Featured Voices for #ASCO26! Get their expert insights into the science & ed sessions, what they view as practice changing & how to bring the learning into the clinic. Be a part of the conversation using the meeting hashtag. bit.ly/42Oaats

English
1
23
57
6.8K
Chul Kim retweetledi
Balazs Halmos
Balazs Halmos@BalazsHalmosMD·
Time to focus on.. the thymus! Relevant experience - principally on thymic carcinomas (28/30 pts) w intriguing signals of activity but also some irAE safety concerns Would just be careful not to interpret more broadly for thymomas where safety concerns had been very prominent re severe irAEs
GIF
Rami Manochakian MD, FASCO Cancer Education@RManochakian

🧵1/3🔥@OncoAlert Hot off the press. ⭐️My co-authors & I are excited to share this just published paper @ClinicalLung on: ✅#RealWorld Assessment of #Efficacy & #Toxicity of #Immune #CheckPointInhibitors (#ICI) in Advanced #Thymic #EpithelialTumors. 👇🏻 sciencedirect.com/science/articl…

English
1
5
16
2.3K
Chul Kim
Chul Kim@chulkimMD·
Honored to serve as Co-Chair for Best of ASCO Washington DC, a free CME-accredited meeting featuring highlights from the ASCO Annual Meeting We have a great line-up of speakers who will discuss the abstracts with the greatest clinical impact Register: bit.ly/4uR0n1E
Chul Kim tweet media
English
1
4
23
864
Laura Alder, MD
Laura Alder, MD@LauraAlderMD·
Honored to serve on @ASCO's expert panel for the Stage IV Non-Small Cell Lung Cancer Living Guidelines! Lung cancer care is evolving rapidly, and I'm excited to work alongside incredible colleagues to ensure clinicians have the most current, evidence-based guidance at their fingertips. 🫁✨ #LCSM #NSCLC
Laura Alder, MD tweet media
English
3
2
46
1.4K
Chul Kim
Chul Kim@chulkimMD·
Join us for a webinar on updates in clinical guidelines for thymic tumors, featuring thought leaders Drs. Gregory Riely (@RielyMD), Nicolas Girard (@nicogirardcurie), Vincent Fang & Clémence Basse. 📅 May 20, 9–10 AM EDT Register: bit.ly/4diIq6s @Itmig_society
Chul Kim tweet media
English
0
5
20
1.9K